Top
image credit: Unsplash

Gilead gets cell therapy boost with FDA clearance of Maryland factory

April 19, 2022

First approved in 2017 for lymphoma, Yescarta was cleared by the FDA for wider use earlier this month, making the regulator’s clearance of the factory a timely boost to Gilead’s manufacturing capacity.

With the most recent OK, Yescarta can now be used earlier for lymphoma patients who either relapse or see their disease become resistant to initial treatment. Previously, Yescarta’s approval was limited to “third-line” treatment, after other therapies and, typically, a stem cell transplant had failed to curb patients’ cancer.

Read More on Biopharma Dive